Neurodegeneration

Neurodegeneration, the progressive loss of structure and function in neurons, is a central concern in longevity medicine, as it significantly impacts healthspan and quality of life. Longevity medicine seeks to understand and mitigate the molecular, environmental, and genetic factors contributing to neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (Johmura et al., 2021)(Phoenix & de Grey, 2007). Addressing these factors and their interactions aims to prevent or delay the onset of neurodegeneration, extending lifespan and cognitive function.

At the molecular level, neurodegeneration is driven by a combination of cellular and biochemical processes that compromise neuronal health and function. Protein misfolding and aggregation are hallmark features of neurodegenerative diseases (Sweeney et al., 2017) (Nikhra, 2017). In Alzheimer's disease, the accumulation of beta-amyloid plaques and tau neurofibrillary tangles disrupt synaptic communication and induce neuronal death. Similarly, in Parkinson's disease, Lewy bodies that contain aggregated alpha-synuclein are considered the main culprit for neurodegeneration, and recent evidence suggests that aggregated alpha-synuclein in mitochondria contributes to oxidative stress-mediated cell death in neurons (Haque et al., 2022) (Li et al., 2023). These protein aggregates trigger a cascade of downstream effects, including oxidative stress, mitochondrial dysfunction, and activation of inflammatory pathways, all of which exacerbate neuronal damage.

Mitochondrial dysfunction is important in neurodegeneration (Nikhra, 2017) (Lin & Beal, 2006). With their high metabolic demand, neurons rely heavily on mitochondria for energy production and calcium buffering. Mitochondrial DNA mutations and excessive production of reactive oxygen species may contribute to energy failure in neurodegenerative diseases (Federico et al., 2012), and impaired electron transport chain activity and disrupted quality-control mechanisms, such as mitophagy, are associated with the initial phases of disease progression (Yang, 2025).

Inflammation is another molecular contributor (Nikhra, 2017). Neuro-inflammation, which involves the activation of microglia and astrocytes, is associated with neurodegenerative diseases, and glial activation can be either neurotoxic or neuroprotective (Kwon & Koh, 2020). The interaction between mitochondrial dysfunction, protein aggregation, and neuroinflammation creates a vicious cycle that eventually leads to neurodegeneration.

While the potential of longevity medicine in the field of neurodegeneration is promising, several challenges and limitations remain. First, the multifactorial nature of Alzheimer's disease, shaped by genetic, environmental, and biological factors, complicates both research and clinical management (Ren et al., 2025). The development of effective therapies is also hindered by the lack of reliable biomarkers to monitor disease progression and therapeutic response (Sweeney et al., 2017).

To address these challenges, future research in longevity medicine should focus on incorporating multi-omics approaches and using electronic health records (Tang et al., 2024) (Ren et al., 2025). By taking a more comprehensive and interdisciplinary approach, longevity medicine can uncover new insights into the aging process and its relationship with neurodegenerative conditions, ultimately leading to the development of more effective interventions.

Lastly, while extending lifespan is one goal, longevity medicine should focus on extending healthspan, or the period of life free from disease and disability. Longevity medicine can significantly impact the quality of life for individuals affected by neurodegenerative diseases by shifting the emphasis towards maintaining cognitive function and overall well-being.

The field of longevity medicine holds great promise in addressing the growing burden of neurodegenerative diseases, such as Alzheimer's, Parkinson's, and ALS. By understanding the complex interplay between aging, molecular mechanisms, and neurodegeneration, longevity research can pave the way for developing targeted interventions that can preserve cognitive function and enhance the overall quality of life for affected individuals.

Finally, the future of longevity medicine in the context of neurodegenerative diseases lies in integrating multidisciplinary approaches, developing reliable biomarkers, and focusing on improving healthspan rather than just lifespan extension. As the global population ages, the successful application of longevity medicine could have a transformative impact on millions affected by these debilitating conditions.